ISA Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Leiden Netherlands (2004)

Organization Overview

First Clinical Trial
2008
NCT00844506
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ISA Pharmaceuticals | ISA Pharmaceuticals B.V.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma in Situ (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Disease Progression (Phase 2)

Lip Neoplasms (Phase 2)

Neoplasms (Phase 2)

Oropharyngeal Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Precancerous Conditions (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 11